Treatment of acute exacerbations of interstitial lung disease

Natalya Azadeh, Teng Moua, Misbah Baqir, Jay H. Ryu

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Introduction: Interstitial lung diseases (ILD) include a broad range of diffuse parenchymal lung disorders of known and unknown etiologies. Patients with ILD can experience acute exacerbations (AE) which are associated with extremely high morbidity and mortality. Little is known about the etiology of AEs, and whether inciting triggers (such as infection) result in an aberrant inflammatory response in a predisposed host. Areas covered: The majority of data regarding AE-ILD comes from the idiopathic pulmonary fibrosis (IPF) population and is extrapolated to other forms of ILD. For the purposes of this review we have summarized the current literature regarding AE of IPF, and when available have included data from AE of other ILDs. Expert commentary: Therapeutic options for AE are limited without definitive treatments available, and the prognosis is often poor. Treatment is mainly based on correcting hypoxemia, looking for reversible etiologies of respiratory decline, and palliation of symptoms. Overall little is known about the pathogenesis of ILDs and AE-ILD, more research is needed in hopes of identifying better treatment options.

Original languageEnglish (US)
Pages (from-to)309-313
Number of pages5
JournalExpert Review of Respiratory Medicine
Issue number4
StatePublished - Apr 3 2018


  • IPF
  • Interstitial lung disease
  • acute
  • exacerbation
  • fibrosis
  • treatment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Treatment of acute exacerbations of interstitial lung disease'. Together they form a unique fingerprint.

Cite this